Novartis R&D day spotlights attractive growth profile, underpinned by

On Dec 2, 2021

Focused medicines company delivering strong operational performance
Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Confident to grow sales 4%+ CAGR through 2026^*, driven by multi-billion dollar sales from Cosentyx^®, Entresto^®, Kesimpta^®, Zolgensma^®, Kisqali^® and Leqvio^®^*^*
Up to 20 new assets with 1-billion dollar sales potential, set to potentially be approved by 2026, to fuel further growth through 2030 and beyond
Cosentyx met primary efficacy endpoint in two hidradenitis suppurativa Ph3 studies, and ianalumab demonstrated efficacy in Ph2b Sjögren’s study¹
Next-generation T-Charge™ platform validated as YTB323 showed 75% CR at 3 months in DLBCL² and PHE885 delivered 100% BOR in multiple myeloma³
Pioneering shift to advanced technology platforms including: Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA

Basel, December 2, 2021 — Novartis today holds an investor event to provide a comprehensive overview of the company’s progress in advancing its industry-leading R&D engine.

Vas Narasimhan, CEO of Novartis, said “Novartis has transformed to become a focused medicines company, building depth in our core therapeutic areas and strength across key technology platforms. We expect to continue delivering strong operational performance, with 4%+ CAGR through to 2026*, driven by the momentum of our multi-billion dollar in-market growth drivers. Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs. We are building the foundation for long-term differential growth by investing in advanced technology platforms and data science. Novartis remains disciplined and shareholder focused in its capital allocation priorities, as we continue to deliver on our strategy”.

New announcements at R&D Day 2021:

Cosentyx, our largest medicine by sales, showed topline results in moderate to severe hidradenitis suppurativa (HS), a potential new indication. Two Phase 3 studies (SUNRISE and SUNSHINE) met their primary endpoint, with more patients treated with Cosentyx achieving a HS Clinical Response (HiSCR), compared with placebo, at week 16. The safety of Cosentyx in HS was consistent with the therapy’s known safety profile. The trials are ongoing to 52 weeks and are expected to complete in H2 2022. Regulatory filings are planned for 2022.

Novartis presents T-Charge™, a next generation CAR-T cell therapy platform, expected to increase CAR-T potency and have important process efficiencies to reduce turnaround time. In first-in-human trials to be presented at ASH 2021, lead candidates YTB323 and PHE885 showed 75% Complete Response in Diffuse Large B-Cell Lymphoma (DLBCL) at three months and 100% Best Overall Response (BOR) in multiple myeloma, respectively. Novartis is developing T-Charge™ as the foundational platform for a wave of potentially…